"Best case scenario for Biodel would be for the FDA to require an additional trial due to the bad data from India and allow Biodel to conduct the trial with the pen injector."
"Assuming Biodel could have the trials completed by July/2011 then a resubmitted NDA would probably obtain a PDUFA date in December,2011 (as Mannkind accomplished in getting a PDUFA date six months from the resubmission for Afrezza)."
"Assuming approval at that time and allowing time to finalize a partnership and set-up manufacturing and obtaining approval would put the launch date in the first quarter of 2013."
"Pipe funding requirements would probably take the share price to the $1.85 range at some point in this time frame."
Just a thought!!!